NEW YORK (GenomeWeb News) – Biodesix today said that it has closed an $8.3 million Series E round of private financing.

The Boulder, Colo.-based molecular diagnostics firm said that new funds accounted for $4.3 million of the financing round, while the remaining $4 million came from the conversion of a convertible note. It said that all of the funds came from existing shareholders in the firm.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.